Sequential Drug Release Achieved with Dual‐Compartment Microcontainers: Toward Combination Therapy (Adv. Therap. 11/2022)

Stimuli-free programmable drug release for combination chemo-therapy.

Combinational chemotherapy capable of targeted delivery and programmable multi-drug release leads to enhanced drug efficacy, and is highly desired for cancer treatment. However, effective approaches for achieving both features in a single treatment are limited. In the present work, we demonstrated programmed delivery of both chemotherapeutic and immunotherapeutic agents with tumor cell targetin...

LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV.

INTRODUCTION Among the available nucleos(t)ide analogues adefovir dipivoxil (ADV) is relatively cheap and widely used in rural area in China. However, there are insufficient data on recommendation for patients with suboptimal response to ADV after 48 weeks of treatment in order to reduce the resistance rate in the long term. The aim of this study was to compare the efficacy and safety of LAM ad...

Microcontainers as an oral drug delivery system

Drug combination therapy increases successful drug repositioning.

Repositioning of approved drugs has recently gained new momentum for rapid identification and development of new therapeutics for diseases that lack effective drug treatment. Reported repurposing screens have increased dramatically in number in the past five years. However, many newly identified compounds have low potency; this limits their immediate clinical applications because the known, tol...

Combination and sequential therapy with PTH and bisphosphonates.

with anti-resorptive agents, such as bisphosphonates, offer the potential for synergistic benefits for patients at high risk of fracture. Although fracture endpoint studies exist for monotherapy with either bisphosphonates or PTH, such studies do not exist for treatment strategies involving combined or sequential use of PTH and bisphosphonates, and only studies with surrogate endpoints currentl...